The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine is set to present new preclinical data this week at both the American Society of Gene and Cell Therapy (ASGCT) and TIDES USA annual meetings.
The focus will be on cardiovascular disease, with Editas Medicine highlighting novel in vivo research efforts. Details about the company's participation and presentations at each conference are available via their official channels.
Editas Medicine recently announced plans to present new preclinical data on gene editing at scientific conferences, with a focus on cardiovascular research earlier this year. The company also reported its first quarter 2026 financial results and provided updates on development programs in its latest earnings release. These developments reflect continued progress in Editas Medicine’s gene editing initiatives.